Article

Dr. Noel G. Boyle Discusses Benefits of Dabigatran Versus Warfarin for Treatment of Atrial Fibrillation

Dr. Noel G. Boyle, Professor of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, talks about new medications that can work as alternatives to warfarin for atrial fibrillation patients who are at risk for stroke.

In addition, Dr. Boyle discusses the benefits of dabigatran (Brand name: Pradaxa) versus warfarin for the treatment of patients with atrial fibrillation. According to Dr. Boyle, advantages of dabigatran include no patient monitoring, fixed dosing, and less drug interactions. Disadvantages of dabigatran include twice daily dosing and no easy method for monitoring, according to Dr. Boyle.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Carrie Kitko
Merrill H. Stewart, MD
Nicolas Ferreyros, managing director, Community Oncology Alliance
Dr Ibrahim Aldoss
Jody Agena, PharmD, MBA, director of pharamcy operations, Virginia Cancer Specialists
Rachel Rohaidy, MD
Mansi Shah, MD
Miriam Freimer, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo